GlassScriptPhysician profile
Michael B Guin
NPI 1093123275
$5,183.98
in general payments reported to CMS, 2019-2025
27 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,030 · 2022: $1,533 · 2023: $76.49 · 2024: $1,350 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,544 · Education: $76.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,544.27 |
| Education | $76.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $600.39 | 2021-2025 | |
| Sk Life Science, INC. | $519.42 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $446.20 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $396.94 | 2021-2024 | |
| Lilly USA, LLC | $376.95 | 2021-2025 | Kisunla, Amyvid, Reyvow |
| Acadia Pharmaceuticals INC | $329.66 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $260.63 | 2021 | |
| Genzyme Corporation | $256.18 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $254.70 | 2021-2024 | Ultomiris |
| Pfizer INC. | $254.53 | 2021-2025 | |
| Amgen INC. | $214.87 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $168.46 | 2022 | |
| Sunovion Pharmaceuticals INC. | $153.37 | 2021-2022 | |
| Lundbeck LLC | $145.39 | 2024-2025 | Vyepti |
| Argenx US, INC. | $122.38 | 2024-2025 | Vyvgart Hytrulo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $120.30 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $91.94 | 2022 | |
| Janssen Pharmaceuticals, INC | $75.80 | 2022 | |
| Ani Pharmaceuticals, INC. | $64.23 | 2024 | Purified Cortrophin Gel |
| Biohaven Pharmaceutical Holding Company LTD. | $61.39 | 2022 | |
| Neurocrine Biosciences, INC. | $61.34 | 2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $60.97 | 2021-2022 | |
| Eisai INC. | $49.49 | 2022-2025 | |
| Ge Healthcare | $38.24 | 2022 | |
| Ucb, INC. | $30.62 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.06 | 2024 | Nuedexta |
| Avion Pharmaceuticals | $14.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Guin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.